BioSpace News Archive

Matt Monaghan, chairman, president and chief executive officer of Invacare Corporation (NYSE: IVC); Kathy Leneghan, senior vice president and chief financial officer; and Lois Lee, director, treasury, investor relations & corporate communications, will participate in 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will participate in the Wedbush PacGrow Healthcare Conference,

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its products AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) topical foam, 1.5%, have been approved for commercial sale in a pilot program in Hainan Boao Lecheng, China.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced the initiation of the APOLLO-CD Phase 2a clinical trial evaluating PRA023 for moderate-to-severe Crohn’s disease (CD), with first patient enrollment.

180 Life Sciences Corp. announced today that Jagdeep Nanchahal, is scheduled to present a key note talk at the British Society for Surgery of the Hand (BSSH) meeting on Thursday September 9, 2021 at 9:00 AM British Standard Time (4:00 AM Eastern Standard Time).

Gaslab Inc., a leader in gas sensing technologies, has released a new low-oxygen safety monitor that holds a sensor capable of measuring potentially dangerous oxygen levels in freezers and other low temperature applications.

ValGenesis, Inc. today announced the appointment of Kevin O’Donnell as Chief Financial Officer, effective August 2 , 2021.

Moderna, Inc. today announced the first participant has been dosed in the Phase 1 study of mRNA-6231, the Company’s mRNA-encoded IL-2 modified for the expansion of regulatory T cells. mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic.

Praxis Precision Medicines , Inc. today announced that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 9:10 a.m. ET.